All Stories

  1. Placental Growth Factor Promotes Endothelial Activation and Inflammatory Remodelling in Pulmonary Hypertension
  2. Effective Arterial Elastance Relates More Closely to Pulsatile Than Resistive Indices During Routine Hemodynamic Assessment of Inoperable CTEPH
  3. Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension
  4. Multimodal investigation of the association between bevacizumab and pulmonary arterial hypertension
  5. Bridging Disciplines in Portopulmonary Hypertension: A Multidisciplinary Call for Harmonized Patient Management
  6. Chronic thromboembolic pulmonary hypertension associated with venous thoracic outlet syndrome: a retrospective case series
  7. Correspondence on: Pulmonary arterial hypertension in adults with Still’s disease: another pulmonary manifestation associated with HLA-DRB1*15–reply
  8. Response to correspondence on: Pulmonary arterial hypertension in adults with Still's disease: another pulmonary manifestation associated with HLA-DRB1*15
  9. Safety and Efficacy of upfront triple therapy including parenteral treprostinil compared to double oral therapy in PAH (TripleTRE): study protocol for a randomized trial
  10. Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study
  11. Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome
  12. The Activin Pathway in Chronic Thromboembolic Pulmonary Hypertension: A Potential Biomarker for Residual Pulmonary Hypertension After Endarterectomy
  13. Diuretic adherence in patients with precapillary pulmonary hypertension: insights from the PHARE study
  14. Drugs targeting novel pathways in pulmonary arterial hypertension
  15. Risk stratification in Eisenmenger syndrome
  16. ERS Congress 2024: highlights from the Pulmonary Vascular Diseases Assembly
  17. Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in CTEPH: Insights From the RACE Trial
  18. Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study
  19. Effect of sotatercept on circulating proteomics in pulmonary arterial hypertension
  20. Thirty years of surgical management of pediatric pulmonary hypertension: Mid-term outcomes following reverse Potts shunt and transplantation
  21. Treatment algorithm for pulmonary arterial hypertension
  22. Medication adherence, related factors and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review
  23. Risk Assessment in Pulmonary Veno-Occlusive Disease: The First Step Towards Future Trials?
  24. Percutaneous atrial septal defect closure in patients with pulmonary arterial hypertension
  25. POINT: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? Yes
  26. Pulmonary veno-occlusive disease: illustrative cases and literature review
  27. The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis
  28. From the microscopic to the macroscopic: clinical–radiological–pathological correlation in pulmonary hypertension
  29. ERS International Congress 2023: highlights from the Pulmonary Vascular Diseases Assembly
  30. Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension with mixed anatomical lesions: a proof of concept
  31. Pulmonary arterial hypertension
  32. Diagnosis and management of pulmonary veno-occlusive disease
  33. New trends in pulmonary hypertension
  34. Reply to Jha
  35. The Influence of Methods for Cardiac Output Determination on the Diagnosis of Precapillary Pulmonary Hypertension: A Mathematical Model
  36. To be or not to be… treated with initial combination therapy, that is the (PAH) question
  37. Erythrocytes are altered in pulmonary arterial hypertension
  38. ERS statement on chronic thromboembolic pulmonary hypertension
  39. Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers
  40. Reply to Jin et al. and to Sun et al.
  41. Sex and gender in pulmonary arterial hypertension
  42. Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs
  43. The isobaric pulmonary arterial compliance in pulmonary hypertension
  44. Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
  45. Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated
  46. Reply to: “Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?”
  47. ERS statement on chronic thromboembolic pulmonary hypertension
  48. Reversible pulmonary hypertension associated with multivisceral Whipple's disease
  49. Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON
  50. Pulmonary Hypertension Complicating Pulmonary Artery Involvement in Pseudoxanthoma Elasticum
  51. Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
  52. Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration
  53. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
  54. Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
  55. Pulmonary arterial hypertension registries: past, present and into the future
  56. Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension
  57. A dynamic prognostic model to predict survival and determine treatment goals in pulmonary arterial hypertension (PAH): the EFORT study
  58. Assembly 13: placing the pulmonary circulation in the heart of ERS
  59. Highlights from the ERS International Congress 2018: Assembly 13 – Pulmonary Vascular Diseases
  60. Clinical trial design and new therapies for pulmonary arterial hypertension
  61. Hépatopathies et maladies vasculaires pulmonaires
  62. Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension
  63. Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension
  64. Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery
  65. Risk stratification in pulmonary arterial hypertension
  66. Évaluation de l’IRM cardiaque dans le suivi des patients ayant une hypertension artérielle pulmonaire (EVITA). IRM cardiaque dans le suivi de l’hypertension artérielle pulmonaire
  67. Pulmonary hypertension associated with neurofibromatosis type 1
  68. Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations
  69. Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension
  70. Portopulmonary hypertension
  71. Factors predicting outcome after pulmonary endarterectomy
  72. Genetic determinants of risk and survival in pulmonary arterial hypertension
  73. Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis
  74. Age, risk and outcomes in idiopathic pulmonary arterial hypertension
  75. Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease
  76. The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?
  77. Outcome of Portopulmonary Hypertension After Liver Transplantation
  78. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial
  79. Risk assessment in pulmonary arterial hypertension
  80. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2 ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study
  81. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension
  82. RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study
  83. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality
  84. La maladie veino-occlusive pulmonaire
  85. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
  86. Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry
  87. Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus
  88. Acute decompensated pulmonary hypertension
  89. Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension
  90. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension
  91. Medical Treatment of Pulmonary Arterial Hypertension
  92. Portopulmonary Hypertension
  93. Exertional dyspnoea in pulmonary arterial hypertension
  94. Are indexed values better for defining exercise pulmonary hypertension?
  95. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study
  96. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension
  97. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
  98. Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension
  99. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study
  100. Validation of a risk assessment instrument for pulmonary arterial hypertension
  101. Pulmonary hypertension due to left heart disease
  102. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study
  103. Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome
  104. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study
  105. Long-term outcome in liver transplantation candidates with portopulmonary hypertension
  106. Gut–Lung Connection in Pulmonary Arterial Hypertension
  107. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
  108. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study
  109. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
  110. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension
  111. Proceedings of Réanimation 2017, the French Intensive Care Society International Congress
  112. A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF
  113. Beyond a single pathway: combination therapy in pulmonary arterial hypertension
  114. BMPR2mutation status influences bronchial vascular changes in pulmonary arterial hypertension
  115. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
  116. Interferon-induced pulmonary hypertension
  117. Pulmonary arterial hypertension in idiopathic inflammatory myopathies
  118. Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study
  119. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension
  120. Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension
  121. International Liver Transplant Society Practice Guidelines
  122. Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension
  123. Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension
  124. Response to Letter Regarding Article, “Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model”
  125. Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure
  126. Pulmonary veno-occlusive disease
  127. Initial dual oral combination therapy in pulmonary arterial hypertension
  128. Resting pulmonary artery pressure of 21–24 mmHg predicts abnormal exercise haemodynamics
  129. A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica
  130. Patients’, relatives’, and practitioners’ views of pulmonary arterial hypertension: A qualitative study
  131. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis
  132. Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease
  133. Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension
  134. Kinetics of Cardiac Output at the Onset of Exercise in Precapillary Pulmonary Hypertension
  135. Infections liées aux cathéters veineux centraux tunnélisés chez les patients ayant une hypertension artérielle pulmonaire traitée par prostacycline intraveineuse
  136. Selexipag for the Treatment of Pulmonary Arterial Hypertension
  137. Genetic counselling in a national referral centre for pulmonary hypertension
  138. Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension
  139. Chronic thromboembolic pulmonary hypertension
  140. Pulmonary arterial hypertension in patients treated with interferon: TABLE 1
  141. Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease
  142. Pulmonary Hypertension Complicating Fibrosing Mediastinitis
  143. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
  144. The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress
  145. Response to Letter Regarding Article, “Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension”
  146. Mitomycin-Induced Pulmonary Veno-Occlusive Disease
  147. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension
  148. New pharmacotherapy options for pulmonary arterial hypertension
  149. Non-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension
  150. Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study: TABLE 1
  151. Criteria for diagnosis of exercise pulmonary hypertension
  152. Characteristics of Pulmonary Arterial Hypertension in Affected Carriers of a Mutation Located in the Cytoplasmic Tail of Bone Morphogenetic Protein Receptor Type 2
  153. Inspiratory muscle function, dynamic hyperinflation and exertional dyspnoea in pulmonary arterial hypertension
  154. Validation of two predictive models for survival in pulmonary arterial hypertension
  155. Systolic and Mean Pulmonary Artery Pressures
  156. Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension
  157. Chemotherapy-Induced Pulmonary Hypertension
  158. Effect of Macitentan on Hospitalizations
  159. Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension
  160. Connective tissue disease associated with pulmonary arterial hypertension: management of a patient with severe haemodynamic impairment
  161. Pulmonary arterial hypertension
  162. Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension
  163. Pulmonary arterial hypertension in patients treated with interferon
  164. Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group
  165. Hypertension pulmonaire et maladies hépatiques
  166. Traitement chirurgical de l’hypertension pulmonaire post-embolique
  167. Traitement de l’hypertension artérielle pulmonaire
  168. Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations
  169. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension
  170. Prognostic value of exercise pulmonary haemodynamics in pulmonary arterial hypertension
  171. The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension
  172. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry
  173. Biomarkers for the prognosis of pulmonary arterial hypertension: Holy grail or flying circus?
  174. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
  175. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension
  176. Right heart failure: Toward a common language
  177. Targeted therapies in pulmonary arterial hypertension
  178. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension
  179. Treatment Goals of Pulmonary Hypertension
  180. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension
  181. Left Ventricular Ejection Time in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension
  182. Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy
  183. Inflammatory Mechanisms in HIV-Associated Pulmonary Arterial Hypertension
  184. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
  185. Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment
  186. Pulmonary arterial hypertension
  187. Calcium-Channel Blockers in Pulmonary Arterial Hypertension
  188. Pathways in pulmonary arterial hypertension: the future is here
  189. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era
  190. Independent Association of Urinary F2-Isoprostanes With Survival in Pulmonary Arterial Hypertension
  191. Pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis
  192. Hemodynamics in Pulmonary Arterial Hypertension: Current and Future Perspectives
  193. The study of risk in pulmonary arterial hypertension
  194. Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal
  195. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension
  196. Renal Replacement Therapy in Patients with Severe Precapillary Pulmonary Hypertension with Acute Right Heart Failure
  197. Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction
  198. Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension
  199. EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism: Figure 1–
  200. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension
  201. Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
  202. Mediastinal Fibrosis Mimicking Proximal Chronic Thromboembolic Disease
  203. Pulmonary hypertension associated with benfluorex exposure
  204. Portopulmonary Hypertension
  205. L’hypertension artérielle pulmonaire associée au VIH
  206. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study
  207. Portopulmonary Hypertension and Hepatopulmonary Syndrome
  208. Optimal management of severe pulmonary arterial hypertension
  209. Systemic lupus erythematosus-associated PAH: is targeting inflammation the key to success?
  210. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease
  211. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival
  212. Pulmonary Arterial Hypertension in a Patient With Cowden Syndrome and Anorexigen Exposure
  213. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies
  214. Treatment of pulmonary arterial hypertension with targeted therapies
  215. The association between resting and mild-to-moderate exercise pulmonary artery pressure
  216. Pulmonary hypertension related to appetite suppressants
  217. Pulmonary Hypertension in Patients With Neurofibromatosis Type I
  218. Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
  219. Prise en charge de l’hypertension artérielle pulmonaire en 2011 : les innovations depuis les recommandations ERS/ESC 2009
  220. Pulmonary veno-occlusive disease: The bête noire of pulmonary hypertension in connective tissue diseases?
  221. Current management approaches to portopulmonary hypertension
  222. Pulmonary arterial hypertension: combination therapy in the modern management era
  223. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals
  224. Pharmacokinetic evaluation of continuous intravenous epoprostenol
  225. Effects of HIV Protease Inhibitors on Progression of Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension in Rats
  226. Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension
  227. Pulmonary veno-occlusive disease: Recent progress and current challenges
  228. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era
  229. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
  230. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension
  231. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
  232. Objectifs thérapeutiques dans l’hypertension artérielle pulmonaire
  233. Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis
  234. Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice
  235. Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying anACVRL1(ALK1) Mutation
  236. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome
  237. Diagnostic et prise en charge de l’hypertension pulmonaire en 2009. Commentaires sur les nouvelles recommandations de l’European Society of Cardiology (ESC) et de l’European Respiratory Society (ERS)
  238. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era
  239. Maladie veino-occlusive et hémangiomatose capillaire pulmonaire
  240. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
  241. Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre
  242. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension
  243. Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension
  244. Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?
  245. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution
  246. Pulmonary Venoocclusive Disease and Failure of Specific Therapy
  247. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
  248. Fatal dissection of the pulmonary artery in pulmonary arterial hypertension
  249. Idiopathic Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease: Similarities and Differences
  250. Pulmonary Arterial Hypertension and HIV Infection
  251. Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence
  252. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease
  253. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France
  254. End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
  255. Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
  256. Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats
  257. Fenfluramine-like cardiovascular side-effects of benfluorex
  258. Pulmonary veno-occlusive disease
  259. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
  260. Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension
  261. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study
  262. Portopulmonary Hypertension
  263. HIV-related pulmonary arterial hypertension: clinical presentation and management
  264. Review: Therapeutic advances in pulmonary arterial hypertension
  265. Pulmonary Veno-Occlusive Disease
  266. Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers ofBMPR2Mutation
  267. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension
  268. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
  269. Immunosuppressive therapy in lupus- and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases
  270. Prevalence of HIV-related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era
  271. Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension
  272. Hypertension pulmonaire postembolique
  273. Hypertension artérielle pulmonaire postembolique tumorale
  274. Pulmonary vascular abnormalities in cirrhosis
  275. Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension
  276. Hypertension portopulmonaire
  277. Cœur pulmonaire chronique postembolique révélant une bêtathalassémie intermédiaire après splénectomie
  278. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
  279. Long term imatinib treatment in pulmonary arterial hypertension
  280. Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension
  281. Pulmonary Arterial Hypertension in France
  282. Mutations of the TGF-β type II receptorBMPR2 in pulmonary arterial hypertension
  283. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
  284. Deleterious Effects of β-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension
  285. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension
  286. Occult alveolar haemorrhage in pulmonary veno-occlusive disease
  287. Clinical Challenges in Pulmonary Hypertension
  288. Pulmonary Endothelin-1 Clearance in Human Pulmonary Arterial Hypertension
  289. Splenectomy and chronic thromboembolic pulmonary hypertension
  290. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
  291. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease
  292. Diagnostic et classification des hypertensions artérielles pulmonaires
  293. Génétique de l’hypertension artérielle pulmonaire: données récentes et applications pratiques
  294. Traitement chirurgical de la maladie thromboembolique pulmonaire chronique
  295. Les traitements de l’hypertension artérielle pulmonaire à l’heure de la T2A. Recommandations du groupe de travail “Maladies vasculaires pulmonaires” de la Société de pneumologie de langue française
  296. Traitement de l’hypertension artérielle pulmonaire
  297. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis
  298. Hypertension artérielle pulmonaire
  299. Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France
  300. Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence
  301. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension
  302. Severe Pulmonary Hypertension during Pregnancy
  303. Bosentan therapy for pulmonary arterial hypertension
  304. Survival with first-line bosentan in patients with primary pulmonary hypertension
  305. Évaluation pronostique de biomarqueurs dans l’hypertension artérielle pulmonaire
  306. Bosentan for the Treatment of Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension
  307. Caractéristiques cliniques, hémodynamiques et génétiques de l’hypertension artérielle pulmonaire familiale
  308. Traitement de l'hypertension artérielle pulmonaire
  309. Treatment of Pulmonary Arterial Hypertension
  310. Pulmonary Hypertension:CT of the Chest in Pulmonary Venoocclusive Disease
  311. Diagnosis and differential assessment of pulmonary arterial hypertension
  312. Endothelin receptor antagonists in pulmonary arterial hypertension
  313. Prostanoid therapy for pulmonary arterial hypertension
  314. Prise en charge thérapeutique de l’hypertension porto-pulmonaire
  315. Automatic quantification of right ventricular function with gated blood pool SPECT
  316. Chronic thromboembolic pulmonary hypertension
  317. Traitement chirurgical de l’hypertension artérielle pulmonaire post-embolique
  318. Prise en charge thérapeutique de l’hypertension porto-pulmonaire
  319. Novel therapeutic perspectives in pulmonary arterial hypertension
  320. Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension
  321. Prognostic Factors for Survival in Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension
  322. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives
  323. Primary pulmonary hypertension: Current therapy
  324. Inhaled Iloprost for Severe Pulmonary Hypertension
  325. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension
  326. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis
  327. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial
  328. Pulmonary Arterial Hypertension: Thin-Section CT Predictors of Epoprostenol Therapy Failure
  329. Pulmonary Artery Pressure–Flow Relations after Prostacyclin in Primary Pulmonary Hypertension
  330. Hypertension artérielle pulmonaire associée aux connectivites
  331. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
  332. PATHOBIOLOGY OF PULMONARY HYPERTENSION
  333. RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION
  334. Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension
  335. Imbalance between Platelet Vascular Endothelial Growth Factor and Platelet-derived Growth Factor in Pulmonary Hypertension
  336. Severe Pulmonary Hypertension in Histiocytosis X
  337. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study
  338. Treatment of pulmonary hypertension secondary to connective tissue diseases
  339. Primary Pulmonary Hypertension Associated With the Use of Fenfluramine Derivatives
  340. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
  341. Treatment of Severe Pulmonary Hypertension Secondary to Connective Tissue Diseases With Continuous IV Epoprostenol (Prostacyclin)
  342. Pulmonary vascular disorders in portal hypertension
  343. Clinical Significance of the Pulmonary Vasodilator Response During Short-term Infusion of Prostacyclin in Primary Pulmonary Hypertension
  344. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.
  345. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.
  346. Pneumopathie aiguë tipidique
  347. Minocycline pneumonitis and eosinophilia. A report on eight patients
  348. Minocycline Pneumonitis and Eosinophilia
  349. Auranofin in steroid dependent asthma.
  350. Prostanoid Treatment for Pulmonary Arterial Hypertension